Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

NCT04500548 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Inadequate accrual rate

Conditions

Constitutional Mismatch Repair Deficiency Syndrome
Hematopoietic and Lymphoid Cell Neoplasm
Lynch Syndrome
Recurrent Lymphoma
Recurrent Malignant Solid Neoplasm
Recurrent Neuroblastoma
Recurrent Primary Central Nervous System Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Neuroblastoma
Refractory Primary Central Nervous System Neoplasm
Xeroderma Pigmentosum

Interventions

PROCEDURE: Biospecimen Collection
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab

Sponsor

National Cancer Institute (NCI)